Table 1.

Patient characteristics, August 1, 2004a

Baseline MeasurePatientsP
AllCinacalcetNo Cinacalcet
n45,48710,33732,788
Age (yr; mean [SD])60.8 (15.2)56.8 (14.8)62.8 (14.9)<0.0001
Age (yr; %)<0.0001
    18 to 4415.421.012.6
    45 to 6440.646.637.8
    65 to 7423.219.924.9
    ≥7520.812.524.6
ESRD duration (yr; mean [SD])3.3 (3.4)4.7 (3.6)3.0 (3.2)<0.0001
ESRD duration (yr; %)<0.0001
    0 to 244.521.849.2
    >255.578.250.8
BMI (kg/m2; mean [SD])26.8 (6.7)27.7 (7.0)26.5 (6.5)<0.0001
Men (%)54.252.255.1<0.0001
Race (%)<0.0001
    black35.547.030.8
    white37.529.040.7
Medicare (%)75.678.074.5<0.0001
History of diabetes (%)51.244.754.3<0.0001
Laboratory values (mean [SD])b
    albumin (g/dl)3.8 (0.5)3.9 (0.4)3.8 (0.5)<0.0001
    Kt/V (delivered)1.6 (0.3)1.6 (0.3)1.6 (0.3)0.0644
    phosphorus (mg/dl)5.5 (1.7)6.3 (1.7)5.3 (1.6)<0.0001
    corrected calcium (mg/dl)9.6 (0.7)9.8 (0.8)9.5 (0.7)<0.0001
    corrected Ca × P (mg2/dl2)52.8 (16.1)60.9 (16.6)50.5 (15.3)<0.0001
    PTH (pg/ml; median [IQR])251.9 (271.2)576.9 (505.8)215.4 (209.6)<0.0001
    PTH (pg/ml; %)<0.0001
    <15024.73.830.5
    150 to 30034.810.738.8
    300 to 60026.238.023.1
    >60014.447.57.6
Primary cause of ESRD (%)<0.0001
    diabetes44.038.746.6
    hypertension28.630.727.7
    glomerulonephritis10.913.79.7
    polycystic kidney disease2.53.22.2
    unknown4.04.53.9
  • a BMI, body mass index; Ca × P, calcium-phosphorus product; IQR, interquartile range; PTH, parathyroid hormone

  • b Values for cinacalcet patients are for the month before cinacalcet initiation.